Medical experts have renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) [1].

The change aims to shift the clinical focus away from ovarian cysts and toward the broader endocrine and metabolic symptoms that characterize the condition [2]. By updating the terminology, experts said the medical community can improve the recognition and overall care of affected women [2].

The update was announced in a peer-reviewed scientific paper published on May 12, 2026 [1]. The new name, Polyendocrine Metabolic Ovarian Syndrome, acknowledges that the syndrome involves multiple hormonal and metabolic disruptions rather than being limited to the ovaries [3].

Gynecologists and endocrinologists said that the previous name was potentially misleading. Because not all patients with the syndrome have cysts on their ovaries, the term "polycystic" did not accurately describe every case [3]. This discrepancy often led to delays in diagnosis or incomplete treatment plans that ignored metabolic health [2].

Women around the world have reacted to the announcement, with some describing the shift as a small win for patient advocacy [4]. The change reflects a growing understanding of how the condition affects the entire endocrine system, including insulin resistance and hormonal imbalances, rather than just reproductive organs [3].

Medical professionals said the transition to PMOS is intended to standardize how the condition is identified globally [1]. This standardization is expected to help clinicians look beyond ultrasound results to identify the syndrome through blood work and symptom history [2].

“The condition formerly called Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS)”

This nomenclature shift represents a transition from a morphology-based diagnosis to a systemic-based diagnosis. By removing the emphasis on 'cysts,' the medical community acknowledges that the condition is a complex metabolic disorder. This may lead to earlier interventions for insulin resistance and other endocrine issues, potentially reducing long-term health risks for patients who do not present with traditional ovarian cysts.